47 results on '"Felizzi, F."'
Search Results
2. Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial
3. EE519 Do We Need Three-State Decision Analytic Models in Metastatic Oncology? An Alternative Approach to Estimate Quality Adjusted Life Years (QALY)
4. P4 Testing SimPy, a Library for Patient-Level Simulations in Python: An Application to Resource Management in Healthcare Systems
5. CO40 Vision-Related Quality of Life in Patients With Diabetic Macular Edema Treated With Brolucizumab 6 Mg vs Aflibercept 2 Mg in the Kestrel and Kite Studies
6. MT27 Budget Impact of a Novel Digital Therapeutic for Amblyopia From a US Private Insurer Perspective
7. EE405 A UK Cost-Minimisation Analysis of Brolucizumab Versus Aflibercept in Diabetic Macular Oedema (DMO)
8. Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial
9. Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial
10. EE438 Assessing the Budget Impact of Automated Diabetic Retinopathy Screening: A Budget Impact Analysis in Germany
11. POSC184 Targeted Literature Review Linking Wet Age-Related Macular Degeneration Real-World Evidence to Healthcare System Capacity and Spending
12. POSC345 Qualitative Literature and Instrument Review to Develop a Clinical Outcome Assessment (COA) Measurement Strategy for Use in Amblyopia Studies
13. POSC154 Cost-Effectiveness of Binocular Treatment for Amblyopia: A Markov Model Framework
14. POSA74 Accounting for Population Heterogeneity Over-Time in Estimating Costs and Outcomes in Cohort-Based Health-Economic Evaluations
15. P48 Joint Modelling Measurable Target Lesions, EQ5D/Utility and Overall Survival: Do We Still Need Partitioned Survival Models?
16. Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer
17. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer
18. PCN245 Opposing Duration of Treatment Effect Assumptions USED in the Health Technology Assessment of a Treatment for Rituximab-Refractory Follicular Lymphoma
19. PNS30 COST-EFFECTIVENESS MODELING FRAMEWORK FOR MATCHING-ADJUSTED-INDIRECT-COMPARISONS IN THE PRESENCE OF CURE ESTIMATES
20. PCN279 PROBABILISTIC SENSITIVITY ANALYSIS: FAST WAYS TO MODEL THE COVARIANCE STRUCTURE
21. PCN76 A COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB FOR PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN PORTUGAL
22. PNS51 SHIFTING THE MARKET ACCESS FRAMEWORK TO INVESTMENT DECISIONS IN EARLY ASSETS
23. PRO114 EQ-5D UTILITY ESTIMATES FOR PATIENTS WITH SYSTEMIC SCLEROSIS (SSC). INSIGHTS FROM THE FOCUSSCED PHASE III EFFICAY AND SAFETY STUDY OF TOCILIZUMAB.
24. ESTIMATION OF LONG-TERM SURVIVAL WITH POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB FOR PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)
25. P3.04-17 Cost-Effectiveness of Atezolizumab for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) in Canada
26. PRM155 - JOINT MODELING OF OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL
27. PRM251 - EVALUATING BUDGET IMPACT OF CURES. MACHINE LEARNING METHODS SHED LIGHT ON WHO CAN BE CURED IN METASTATIC MELANOMA
28. P1.01-052 Patient-Reported Outcomes (PROs) in OAK: A Phase III Study of Atezolizumab vs Docetaxel in Non-Small-Cell Lung Cancer (NSCLC)
29. Rate of Hospitalization Due To Adverse Event and Length of Stay for Atezolizumab in Second and Third Line Metastatic Non-Small Lung Cancer (NSCLC) Using Phase 3 Oak Study
30. PCN194 - Rate of Hospitalization Due To Adverse Event and Length of Stay for Atezolizumab in Second and Third Line Metastatic Non-Small Lung Cancer (NSCLC) Using Phase 3 Oak Study
31. Excitotoxicity Downregulates TrkB.FL Signaling and Upregulates the Neuroprotective Truncated TrkB Receptors in Cultured Hippocampal and Striatal Neurons
32. Qualitative Exploration of the Visual Function Impairments and Health-Related Quality of Life Impacts of Amblyopia in Adult and Pediatric Populations.
33. Efficacy and Safety of Brolucizumab, Aflibercept, and Ranibizumab for the Treatment of Patients with Visual Impairment Due to Diabetic Macular Oedema: A Systematic Review and Network Meta-Analysis.
34. The Amblyopia Quality of Life (AmbQoL): Development and Content Validation of a Novel Health-Related Quality of Life Instrument for Use in Adult and Pediatric Amblyopia Populations.
35. A Social Media Listening Study to Understand the Unmet Needs and Quality of Life in Adult and Pediatric Amblyopia Patients.
36. Machine Learning Methods in Health Economics and Outcomes Research-The PALISADE Checklist: A Good Practices Report of an ISPOR Task Force.
37. Mixture Cure Models in Oncology: A Tutorial and Practical Guidance.
38. Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma.
39. Semiparametric estimation of the cure fraction in population-based cancer survival analysis.
40. US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma.
41. Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France.
42. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
43. Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer.
44. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer.
45. Enhanced cellular sensitivity from partitioning the integrin receptors into multiple clusters.
46. Network-of-queues approach to B-cell-receptor affinity discrimination.
47. Analyzing and constraining signaling networks: parameter estimation for the user.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.